Empaglif-M combines 2 anti-hyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes: Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin, a member of the biguanide class. Empaglif-M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Empagliflozin and Metformin hydrochloride is appropriate.
FR
DE